Clinical Trial Update: MSB11022 in Moderate to Severe Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial update for MSB11022 in moderate to severe rheumatoid arthritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MSB11022

Snippet

Sponsor: Fresenius Kabi SwissBioSim GmbH | Conditions: Moderate to Severe Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2019-04-23